Advances and Challenges in Alzheimer's Disease: a Comprehensive Review of Treatment Strategies, Diagnostic Tools, and Future Directions

Abstract

"Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline and memory loss, primarily caused by the accumulation of amyloid-beta plaques and neurofibrillary tangles in the brain". Current therapeutic strategies focus on symptomatic relief, with acetylcholinesterase (AChE) inhibitors being a mainstay in treatment. However, the efficacy of these inhibitors is limited by their poor "bioavailability and inability to effectively cross the blood-brain barrier (BBB)". "Recent advances in nanotechnology have shown promise in overcoming these challenges through the development of nanoparticle-mediated delivery systems". These systems offer enhanced drug stability, targeted delivery, and controlled release, potentially improving the therapeutic outcomes for AD patients. This study explores the formulation of nanoparticle-based delivery systems for AChE inhibitors, evaluating their physicochemical properties, BBB permeability, and therapeutic efficacy. The include optimizing nanoparticle "size, surface charge, and composition to enhance BBB" penetration and drug release profiles. "In vitro and in vivo studies are conducted to assess" the biocompatibility, neuroprotective effects, and cognitive benefits of the formulated nanoparticles. Preliminary results indicate that nanoparticle-mediated delivery significantly enhances the bioavailability and efficacy of AChE inhibitors compared to conventional delivery methods. This research contributes to the growing field of nanomedicine, providing a foundation "for the development of more effective therapeutic strategies for Alzheimer's disease". The potential of nanoparticle-mediated delivery systems to revolutionize AD treatment underscores the importance of continued innovation in this area, paving "the way for improved patient outcomes and quality of life".